Cogent Biosciences, Inc.
NASDAQ:COGT · NASDAQ Global Select
+$0.88 today
Vol 4.89M · Avg 2.15M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-51.7%
avg -57.6%
ROIC
-38.1%
avg -53.3%
ROA
-35.1%
avg -42.4%
Analysis
ROA is currently the strongest return metric at -35.1% versus its period average of -42.4%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Andrew R. Robbins | President, Chief Executive Officer & Director | $1.32M | — | 50 | $160,000.00 | 0.09% |
Jessica Sachs | Chief Medical Officer | $896,623.00 | — | 51 | $133,938.00 | 0.08% |
John Edward Robinson | Chief Scientific Officer | $868,743.00 | — | 52 | $140,002.00 | 0.08% |
John L. Green | Chief Financial Officer & Principal Accounting Officer | $834,275.00 | — | 46 | $140,002.00 | 0.08% |
Cole Pinnow | Chief Commercial Officer | $754,602.00 | — | 51 | $311,450.00 | 0.18% |
Brad Barnett | Chief Technology Officer | — | — | — | — | — |
Dana R. Martin | Senior Vice President of Medical Affairs & Chief Patient Officer | — | — | — | — | — |
Evan D. Kearns | Chief Legal Officer & Corporate Secretary | — | — | 46 | $17,901.00 | 0.01% |
Christi Waarich | Senior Director of Investor Relations | — | — | — | — | — |
Rachael Easton | Senior Vice President of Clinical Development | — | — | — | — | — |
Abb Hayden | Senior Vice President of Sales | — | — | — | — | — |
Erin Schellhammer | Chief People Officer | — | — | — | — | — |
Brad Fell | Senior Vice President of Chemistry | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
1
$25.00M
Sells
6
$382.20M
Net Sentiment
$357.20M
Net selling
Most Active
Fairmount Funds Management LLC
3 transactions
Analysis
Insiders reported 1 buys worth $25.00M and 6 sells worth $382.20M over the last 12 months. That adds up to net selling of $357.20M. Fairmount Funds Management LLC was the most active insider with 3 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A4 analysts |
| Revenue | N/A | N/A | +52.4% | +48.4% (11yr)5 analysts |
| Net Income | N/A | N/A | N/A | N/A5 analysts |
| EBIT | N/A | N/A | N/A | N/A5 analysts |
Analysis
Recent growth has been strongest in Revenue at +52.4% over three years. Forward estimates point to Revenue at +48.4% (11yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
ImmunityBio, Inc.
NASDAQ:IBRX
$7.47B
Liquidia Corporation
NASDAQ:LQDA
$6.12B
Denali Therapeutics Inc.
NASDAQ:DNLI
$3.79B
Arcus Biosciences, Inc.
NYSE:RCUS
$2.47B
89bio, Inc.
ETNB
$2.20B
Ocular Therapeutix, Inc.
NASDAQ:OCUL
$2.16B
Agios Pharmaceuticals, Inc.
NASDAQ:AGIO
$2.02B
Galapagos N.V.
GLPG
$1.84B
Viridian Therapeutics, Inc.
NASDAQ:VRDN
$1.52B
Recursion Pharmaceuticals, Inc.
NASDAQ:RXRX
$1.43B
Who manages COGT?
Cogent Biosciences, Inc. (COGT) lists 13 active executives. The top listed executive is Jessica Sachs, Chief Medical Officer.
Are COGT insiders buying or selling?
Recent insider activity shows net selling of $232.13M.
Explore More
Continue the stock analysis
Jump to another research area for this company.